Recursion Pharmaceuticals, Inc. (RXRX) income statement
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/3017% below fair value
$2.45−0.27 (-9.93%)
Close on Nov 20, 2026Market cap $1.31BP/E –Yield –
Recursion Pharmaceuticals, Inc. financial ratios
See a number that looks wrong?